期刊
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
卷 205, 期 12, 页码 1461-1469出版社
AMER THORACIC SOC
DOI: 10.1164/rccm.202109-20430C
关键词
obstructive sleep apnea; drug therapy; carbonic anhydrase inhibition; pharmacology; RCT
资金
- Swedish State Funds for Clinical Research LUA/ALF [ALFGBG-721251]
- Swedish Heart and Lung Foundation [20180585]
- Desitin Arzneimittel (Hamburg, Germany) Project sulthiame OSA
- Swedish Heart-Lung Foundation [20180585] Funding Source: Swedish Heart-Lung Foundation
This study explored the safety and tolerability of the carbonic anhydrase inhibitor sulthiame (STM) in patients with obstructive sleep apnea (OSA). The results showed that STM had a satisfactory safety profile in patients with moderate and/or severe OSA, and it significantly reduced the frequency of OSA events. Therefore, larger clinical studies of STM in OSA are justified.
Rationale: Current therapies for obstructive sleep apnea (OSA) are limited by insufficient efficacy, compliance, or tolerability. An effective pharmacological treatment for OSA is warranted. Carbonic anhydrase inhibition has been shown to ameliorate OSA. Objectives: To explore safety and tolerability of the carbonic anhydrase inhibitor sulthiame (STM) in OSA. Methods: A 4-week double-blind, randomized, placebo-controlled dose-guiding trial was conducted in patients with moderate and/or severe OSA not tolerating positive airway pressure treatment. Measurements and Main Results: Intermittent paresthesia was reported by 79%, 67%, and 18% of patients receiving 400 mg STM (n = 34), 200 mg STM (n =12), and placebo (n = 22), respectively. Dyspnea was reported after 400 mg STM (18%). Six patients in the higher dose group withdrew because of adverse events. There were no serious adverse events. STM reduced the apnea-hypopnea index from 55.2 to 33.0 events/h (-41.0%) in the 400-mg group and from 61.1 to 40.6 events/h (-32.1%) after 200 mg (P < 0.001 for both). Corresponding placebo values were 53.9 and 50.9 events/h (-5.4%). The apnea-hypopnea index reduction threshold of >= 50% was reached in 40% of patients after 400 mg, 25% after 200 mg, and 5% after placebo. Mean overnight oxygen saturation improved by 1.1% after 400 and 200 mg (P < 0.001 and P = 0.034, respectively). Patient-related outcomes were unchanged. Conclusions: STM showed a satisfactory safety profile in moderate and/or severe OSA. STM reduced OSA, on average, by more than 20 events/h, one of the strongest reductions reported in a drug trial in OSA. Larger scale clinical studies of STM in OSA are justified.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据